Exclusive Summary

• Backed by dual US-FDA and UK-MHRA GMP certifications and already registered in the US, providing an ultimate regulatory endorsement for rapid market access across both mature and emerging countries.
• Functioning as a first-line foundational therapy for edema associated with heart and renal blockages, capturing massive and stable terminal demand driven by over 64 million global heart failure patients.
• Offering vastly superior and reliable oral bioavailability compared to classic furosemide, the complete spectrum of dosage strengths (0.5mg/1mg/2mg) perfectly facilitates the individualized diuretic regimens mandated by global guidelines.
• Completely free from patent barriers and empowered by the scaled manufacturing capabilities of China, this distribution partnership guarantees aggressive pricing power and lucrative profit margins for overseas licensees.